IP Library Granted Patent US 8,725,243
Granted Patent B2
US 8,725,243 · App. 11/321,898 · Granted May 13, 2014

Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,725,243
App. No.
11/321,898
Granted
May 13, 2014
Kind
B2
Abstract

The present invention provides systems and methods for managing epilepsy. In one embodiment, a method of the present invention characterize a patient's propensity for a future epileptic seizure and communicates to the patient and/or a health care provider a therapy recommendation. The therapy recommendation is typically a function of the patient's propensity for the future epileptic seizure.

Claims (27)

1. A method of preventing an epileptic seizure comprising:

a first characterizing step, comprising characterizing a patient's propensity for an onset of a future epileptic seizure;

communicating to the patient and/or a health care provider a first therapy recommendation, wherein the first therapy recommendation is selected from a plurality of therapy recommendations based on the patient's propensity for the onset of the epileptic seizure characterized in the first characterizing step;

a second characterizing step after said first characterizing step, comprising characterizing the patient's propensity for an onset of a future epileptic seizure; and

communicating to the patient and/or a health care provider a second therapy recommendation, wherein the second therapy recommendation is different than the first therapy recommendation and is selected from the plurality of therapy recommendations based on the patient's propensity for the onset of the epileptic seizure characterized in the second characterizing step.

2. The method of claim 1 wherein the first and second characterizing steps each comprise characterizing a neural state of a patient.

3. The method of claim 2 wherein first and second characterizing steps each comprise measuring one or more patient dependent parameters.

4. The method of claim 3 wherein the patient dependent parameters comprise EEG signals.

5. The method of claim 4 wherein the measured EEG signals are measured using an intracranial electrode array.

6. The method of claim 1 wherein the first and second therapy recommendations each comprise an instruction to administer an acute dosage of an anti-epileptic agent.

7. The method of claim 6 wherein the first and second therapy recommendations each comprise dosage information for the anti-epileptic agent, wherein the dosage is selected based on the patient's characterized propensity for the onset of the future epileptic seizure.

8. The method of claim 7 wherein the patient's characterized propensity for the onset of the future epileptic seizure is indicative of a seizure onset time parameter, the dosage information comprising a dose inversely related to the time parameter.

9. The method of claim 7 wherein the patient's characterized propensity for the onset of the future epileptic seizure is indicative of a probability parameter, the dosage information comprising a dose directly related to the probability parameter.

10. The method of claim 7 wherein the dosage information corresponding to at least one of the first and second therapy recommendations is a dose selected to be lower than an FDA-approved dose for the anti-epileptic agent.

11. The method of claim 7 wherein the dosage information corresponding to at least one of the first and second therapy recommendations is a dose selected to be higher than an FDA-approved dose for the anti-epileptic agent.

12. The method of claim 7 wherein the dosage information corresponding to at least one of the first and second therapy recommendations is a dose selected to be equivalent to an FDA-approved dose for the anti-epileptic agent.

13. The method of claim 6 wherein the first and second therapy recommendations each specifies a form of the anti-epileptic agent, a formulation of the anti-epileptic agent, and/or a route of administration of the anti-epileptic agent.

14. The method of claim 1 wherein the first and second therapy recommendations each comprises electrical stimulation of a vagus nerve.

15. The method of claim 1 wherein:

the first therapy recommendation comprises an instruction to administer a first dosage of an anti-epileptic agent; and

the second therapy recommendation comprises an instruction to administer a second dosage of the anti-epileptic agent, said second dosage being different than the first dosage.

16. The method of claim 1 wherein:

the first therapy recommendation comprises an instruction to administer a first dosage of an anti-epileptic agent; and

the second therapy recommendation comprises an instruction to administer a second dosage of the anti-epileptic agent greater than the first dosage, wherein the patient's propensity for the onset of the epileptic seizure characterized in the second characterizing step is greater than the patient's propensity for the onset of the epileptic seizure characterized in the first characterizing step.

17. The method of claim 1 wherein:

the first therapy recommendation comprises an instruction to administer a dosage of a first pharmacological agent; and

the second therapy recommendation comprises an instruction to administer a dosage of a second pharmacological agent different than the first pharmacological agent.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Oct 30, 2024
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: LIVANOVA USA, INC.
Reel/Frame 069072/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2024
From: LIVANOVA INC.; LIVANOVA USA INC.
To: DILORENZO BIOMEDICAL, LLC
Reel/Frame 067508/0068 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: ACF FINCO I LP
To: LIVANOVA USA, INC.
Reel/Frame 057552/0378 →
RELEASE OF SECURITY INTEREST Recorded Aug 16, 2021
From: ARES CAPITAL CORPORATION, AS AGENT FOR THE LENDERS
To: LIVANOVA USA, INC.
Reel/Frame 057189/0001 →
SECURITY INTEREST Recorded Aug 16, 2021
From: LIVANOVA USA, INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 057188/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 30, 2020
From: LIVANOVA USA, INC.
To: ACF FINCO I LP, AS COLLATERAL AGENT
Reel/Frame 054881/0784 →
PATENT SECURITY AGREEMENT Recorded Jun 17, 2020
From: LIVANOVA USA, INC.
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 053673/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2013
From: NEUROVISTA CORPORATION
To: CYBERONICS, INC.
Reel/Frame 030192/0408 →
SECURITY AGREEMENT Recorded Sep 14, 2012
From: NEUROVISTA CORPORATION
To: CYBERONICS, INC.
Reel/Frame 028959/0395 →
CHANGE OF NAME Recorded Jun 5, 2007
From: BIONEURONICS CORPORATION
To: NEUROVISTA CORPORATION
Reel/Frame 019385/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2006
From: DILORENZO, DANIEL J.; LEYDE, KENT W.
To: BIONEURONICS CORPORATION
Reel/Frame 017322/0434 →